Ex Vivo Visualization of Distribution of Intravitreal Injections in the Porcine Vitreous and Hydrogels Simulating the Vitreous.

hydrogel intravitreal drug delivery magnetic resonance imaging vitreous body vitreous substitute

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
27 Feb 2023
Historique:
received: 30 01 2023
revised: 23 02 2023
accepted: 24 02 2023
medline: 30 3 2023
entrez: 29 3 2023
pubmed: 30 3 2023
Statut: epublish

Résumé

The characterization of intravitreal dosage forms with regard to their behavior in vivo is usually explored in preclinical development through animal studies. In vitro vitreous substitutes (VS) to simulate the vitreous body for preclinical investigations have so far been insufficiently studied. To determine a distribution or concentration in the mostly gel-like VS, extraction of the gels is required in many cases. This destroys the gels, which makes a continuous investigation of the distribution impossible. In this work, the distribution of a contrast agent in hyaluronic acid agar gels and polyacrylamide gels was studied by magnetic resonance imaging and compared with the distribution in ex vivo porcine vitreous. The porcine vitreous served as a surrogate for human vitreous since both are similar in their physicochemical properties. It was shown that both gels do not completely represent the porcine vitreous body, but the distribution in the polyacrylamide gel is similar to that in the porcine vitreous body. In contrast, the distribution throughout the hyaluronic acid agar gel is much faster. It was also shown that anatomical features such as the lens and the interfacial tension to the anterior eye chamber could have an influence on the distribution that is difficult to reproduce using in vitro VS. However, with the presented method, new in vitro VS can be investigated continuously without destruction in the future, and thus their suitability as a substitute for the human vitreous can be verified.

Identifiants

pubmed: 36986647
pii: pharmaceutics15030786
doi: 10.3390/pharmaceutics15030786
pmc: PMC10056607
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Drug Discov Today. 2008 Feb;13(3-4):135-43
pubmed: 18275911
Annu Int Conf IEEE Eng Med Biol Soc. 2007;2007:6407-10
pubmed: 18003488
Drug Deliv Transl Res. 2022 Jun;12(6):1355-1375
pubmed: 34382178
Eur J Pharm Sci. 2017 Nov 15;109:233-243
pubmed: 28823853
Prog Retin Eye Res. 2000 May;19(3):323-44
pubmed: 10749380
Biomed Tech (Berl). 2012 Sep 06;57 Suppl 1:
pubmed: 23096337
Eur J Pharm Biopharm. 2018 Oct;131:82-91
pubmed: 30055255
Expert Opin Biol Ther. 2013 Feb;13(2):157-67
pubmed: 23190450
Surv Ophthalmol. 2011 Jul-Aug;56(4):300-23
pubmed: 21601902
J Biomed Mater Res B Appl Biomater. 2021 Aug;109(8):1156-1176
pubmed: 33319466
Meat Sci. 1993;33(3):319-31
pubmed: 22060150
Biorheology. 1994 Jul-Aug;31(4):327-38
pubmed: 7981433
Graefes Arch Clin Exp Ophthalmol. 2011 Dec;249(12):1821-9
pubmed: 21845390
Retina. 2012 Jan;32(1):172-6
pubmed: 21878844
Eur J Pharm Biopharm. 2020 Aug;153:130-149
pubmed: 32445965
Anat Rec (Hoboken). 2022 Jan;305(1):199-208
pubmed: 33843149
Int J Pharm. 2017 Apr 30;522(1-2):119-127
pubmed: 28232270
Biochimie. 2002 Apr;84(4):295-302
pubmed: 12106907
Clin Exp Ophthalmol. 2016 Sep;44(7):597-609
pubmed: 26891415
J Ocul Pharmacol Ther. 2015 Feb;31(1):11-6
pubmed: 25562126
Curr Eye Res. 2014 Jul;39(7):752-7
pubmed: 24256543
Macromol Biosci. 2021 Aug;21(8):e2100066
pubmed: 33987966
Prog Retin Eye Res. 2010 Nov;29(6):466-75
pubmed: 20452456
Eye (Lond). 2008 Oct;22(10):1214-22
pubmed: 18309340
J Pharm Sci. 2015 Oct;104(10):3330-42
pubmed: 26108574
J Pharm Sci. 2014 Feb;103(2):517-26
pubmed: 24311438
Biomed Res Int. 2014;2014:351804
pubmed: 24877085
Pharmaceutics. 2020 Mar 16;12(3):
pubmed: 32188045
Acta Biomater. 2011 Mar;7(3):921-35
pubmed: 21050899
Curr Eye Res. 1997 Jul;16(7):663-9
pubmed: 9222083
Eye (Lond). 1987;1 ( Pt 2):254-62
pubmed: 3308528
Eur J Pharm Biopharm. 2021 Sep;166:87-93
pubmed: 34102300
Biophys J. 2015 Nov 17;109(10):2171-81
pubmed: 26588575
Pharmaceutics. 2018 May 29;10(2):
pubmed: 29844284
Exp Eye Res. 2005 Nov;81(5):561-9
pubmed: 15949799
Mediators Inflamm. 2012;2012:148039
pubmed: 22973072

Auteurs

Tobias Auel (T)

Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
Center of Drug Absorption and Transport, Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany.

Lara Paula Scherke (LP)

Center of Drug Absorption and Transport, Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany.

Stefan Hadlich (S)

Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.

Susan Mouchantat (S)

Institute of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475 Greifswald, Germany.

Michael Grimm (M)

Center of Drug Absorption and Transport, Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany.

Werner Weitschies (W)

Center of Drug Absorption and Transport, Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany.

Anne Seidlitz (A)

Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
Center of Drug Absorption and Transport, Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, 17489 Greifswald, Germany.

Classifications MeSH